menu
    • menu
    [{"orgOrder":0,"company":"Wisconsin Medical Cyclotron & Radiopharmacy","sponsor":"Cornerstone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Lipoic acid","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wisconsin Medical Cyclotron & Radiopharmacy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Medical College of Wisconsin","highestDevelopmentStatusID":"7","companyTruncated":"Wisconsin Medical Cyclotron & Radiopharmacy \/ Medical College of Wisconsin"}]

    Find Clinical Drug Pipeline Developments & Deals by Wisconsin Medical Cyclotron & Radiopharmacy

    Menu

    Wisconsin Medical Cyclotron & Radiopharmacy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wisconsin Medical Cyclotron & Radiopharmacy

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Devimistat,Gemcitabine,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Cornerstone Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimist...

                            Details : CPI-613® (devimistat) is a first-in-class clinical lead compound of Cornerstone, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.

                            Brand Name : CPI-613

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Devimistat,Gemcitabine,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cornerstone Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth